Understanding ASAM's Stimulant Guidelines
Episode Overview
Contingency management remains the gold standard for stimulant use disorder treatment. There are no FDA-approved medications specifically for stimulant withdrawal. Close monitoring is crucial when prescribing controlled substances to those with stimulant use disorder. Special populations require tailored approaches, including adolescents and pregnant women. Addressing co-occurring conditions is vital in the treatment of stimulant use disorder.
"Deaths involving all stimulants increased more than 12-fold between 2012 and 2021."
This episode sheds light on the personal battles against stimulant addiction, as Darlene Petersen, MD, and Paula Cook, MD, dissect ASAM's new Clinical Treatment Guidelines for Stimulants. They provide a comprehensive overview of the guidelines, focusing on identification, diagnosis, and treatment of stimulant use disorders. From the shocking rise in stimulant-related deaths to the lack of FDA-approved medications for treatment, the discussion is both sobering and enlightening.
The hosts explore effective treatments like contingency management and psycho-behavioural therapies, while also addressing special populations such as adolescents and pregnant women. They highlight the importance of considering co-occurring conditions and the necessity for close monitoring when prescribing controlled substances. The episode is packed with practical advice for healthcare professionals and offers a clear picture of the current stimulant crisis.
As they unravel these complex issues, listeners are left with a deeper understanding of the challenges faced by those battling stimulant addiction. What can be done to better support individuals on their recovery journey? Tune in to find out.